studies

breast cancer (BC), HER inhibitor vs. lapatinib, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsEGF104900, 2010 0.74 [0.57; 0.96] 0.74[0.57; 0.96]EGF104900, 201010%291NAnot evaluable progression or deaths (PFS)detailed resultsEGF104900, 2010 0.74 [0.58; 0.94] 0.74[0.58; 0.94]EGF104900, 201010%296NAnot evaluable objective responses (ORR)detailed resultsEGF104900, 2010 1.56 [0.68; 3.59] 1.56[0.68; 3.59]EGF104900, 201010%296NAnot evaluable0.55.01.0relative treatment effectwww.metaEvidence.org2024-06-29 18:30 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 64,370,336,147,145,355,337,146,317,4,319,144,356,351,357,352,354,353,358,359,324,142,305,306,98,96,269,60,143,270,140,240,3 - treatments: 712,429,903,472,969,902,1321,643,641,640,427,910,430,976,909,966,917,1013,1025,916,977,1029,1017,911,428,971,913,912,918,965,1067,978,915,914,973,974,702,1313,498,1314,368,1301,1412,1298,1299,1334,1332,1303,1325,1320,1305,1300,1429,1324,1335,1307,1322,1319,718,422,1304,421,1312,1326,1368,1373,1309,1302,1308